[Lab] CPC cagri — Janoshik came back 98.4% against a claimed 97.5%
Title says it — CPC cagri — Janoshik came back 98.4% against a claimed 97.5% — so here is the boring supporting detail that makes it worth anything.
The relevant figures are 98.4% and 97.5%, and they come from the same log I have kept the whole time.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
I will update this if the picture changes rather than quietly leaving it up.
- CPCPC source pageChinese Peptide Company Co., Ltd. · Hangzhou · 93% here, rank 12 · shop at chinesepeptidecompany.net →
nofollow and sponsored; nobody here is paid for it.best — the order this archive was captured in
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 97.6% against a claimed 97.5%, and I posted it because the log needs entries.
Independent result added to the log. Thank you for paying for it — there are very few on this compound.
[removed by moderator]
Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
That result is preclinical.
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.
the co-agonism argument is about complementary mechanisms
the interesting data is the combination, not the monotherapy
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
Reading the trial literature on this without misleading yourself.
Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.
Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.
Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.
Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
nothing here is approved as a standalone product and research material is not for human use
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
amylin analogue, different receptor family, different story
Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.
Which receptor family are you attributing that effect to?
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
nothing containing this is approved as a standalone product
Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.
- 1Amylin is co-secreted with insulin and acts on satiety and gastric emptying…9 comments in this branch · started by u/emil_agyeman
- 2Independent result added to the log. Thank you for paying for it — there are…7 comments in this branch · started by u/ledger_mod